- Home
- PESI vs SKYE Comparison
PESI vs SKYE Comparison
Compare PESI & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PESI
- SKYE
- Stock Information
- Founded
- PESI 1990
- SKYE 2012
- Country
- PESI United States
- SKYE United States
- Employees
- PESI N/A
- SKYE N/A
- Industry
- PESI Environmental Services
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- PESI Industrials
- SKYE Health Care
- Exchange
- PESI Nasdaq
- SKYE Nasdaq
- Market Cap
- PESI 186.4M
- SKYE 73.4M
- IPO Year
- PESI 1992
- SKYE N/A
- Fundamental
- Price
- PESI $11.07
- SKYE $4.61
- Analyst Decision
- PESI
- SKYE Buy
- Analyst Count
- PESI 0
- SKYE 6
- Target Price
- PESI N/A
- SKYE $16.60
- AVG Volume (30 Days)
- PESI 124.4K
- SKYE 2.0M
- Earning Date
- PESI 08-07-2025
- SKYE 08-08-2025
- Dividend Yield
- PESI N/A
- SKYE N/A
- EPS Growth
- PESI N/A
- SKYE N/A
- EPS
- PESI N/A
- SKYE N/A
- Revenue
- PESI $59,419,000.00
- SKYE N/A
- Revenue This Year
- PESI $23.71
- SKYE N/A
- Revenue Next Year
- PESI $86.33
- SKYE N/A
- P/E Ratio
- PESI N/A
- SKYE N/A
- Revenue Growth
- PESI N/A
- SKYE N/A
- 52 Week Low
- PESI $6.25
- SKYE $1.14
- 52 Week High
- PESI $16.25
- SKYE $7.60
- Technical
- Relative Strength Index (RSI)
- PESI 67.56
- SKYE 74.70
- Support Level
- PESI $9.78
- SKYE $3.41
- Resistance Level
- PESI $10.60
- SKYE $5.75
- Average True Range (ATR)
- PESI 0.34
- SKYE 0.60
- MACD
- PESI 0.05
- SKYE 0.17
- Stochastic Oscillator
- PESI 84.87
- SKYE 69.27
About PESI Perma-Fix Environmental Services Inc.
Perma-Fix Environmental Services Inc is a provider of both nuclear services and the management of nuclear and mixed waste. The company operates through two segments: The treatment segment offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.